Daiichi Sankyo
Khalid Mirza is a seasoned professional in global market access and pricing, currently serving as Senior Director at Daiichi Sankyo, Inc., where responsibilities include leading global pricing and access initiatives for the oncology product ENHERTU across over 20 countries. Prior to this role, Khalid held key positions at Merck, contributing to the pricing strategy for the KEYTRUDA franchise and enhancing global market access strategies. Khalid's career began at Novartis, providing business analysis support for various pharmaceuticals. Khalid holds a Master of Public Health in Health Management & Policy and a Bachelor of Science in Microbiology from the University of Massachusetts Amherst.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.